đź’¨ Abstract

On May 2025, Metagenomi Inc. (MGX) reported a first-quarter loss of $25 million, or 68 cents per share, missing Wall Street's estimates of a 62 cents per share loss. The genetic medicines company based in Emeryville, California, reported revenue of $4.1 million for the quarter.

Courtesy: wtop.com